Lucas Harrington is a venture capital investor at SciFounders who earned his PhD in Jennifer Doudna's lab at UC Berkeley and co-founded Mammoth Biosciences with her, giving him deep hands-on CRISPR therapeutics experience. He actively leads Mammoth's therapeutics business as CSO while simultaneously serving as a general partner at SciFounders, making him one of the few investors who is building a frontier therapeutics company while backing other deep-tech founders.

• Focuses heavily on the strategic nuances of biotech partnerships, advising founders to prioritize long-term cultural alignment and internal champions over high upfront payments, drawing from experiences closing deals at Mammoth Biosciences.
• Deep interest in the technical frontiers of gene editing, specifically innovations in delivery mechanisms like NanoCas that allow for compact, single-vector transport to target tissues such as muscle or liver.
• Advocacy for responsible, rigorously regulated research into heritable embryo editing, recently launching a public benefit corporation dedicated to determining if the technology can be safe enough to prevent severe genetic diseases.
• Appetite for practical AI integration in workflow tools, expressing a specific willingness to pay for email clients that effectively use LLMs to understand conversation context better than current market leaders.
• Concerns regarding the broader landscape of American scientific innovation, particularly noting the decline in domestic life sciences literature and the need for policies that protect commercial leadership in biotech.